MedPath

Besivance

These highlights do not include all the information needed to use Besivance safely and effectively. See full prescribing information for Besivance. Besivance (besifloxacin ophthalmic suspension) 0.6%Sterile topical ophthalmic dropsInitial U.S. Approval: 2009

Approved
Approval ID

c326263e-4b55-41b6-b862-c970668669ec

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Apr 1, 2009

Manufacturers
FDA

Physicians Total Care, Inc.

DUNS: 194123980

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

Besifloxacin

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code54868-6282
Application NumberNDA022308
Product Classification
M
Marketing Category
C73594
G
Generic Name
Besifloxacin
Product Specifications
Route of AdministrationOPHTHALMIC
Effective DateJuly 22, 2011
FDA Product Classification

INGREDIENTS (9)

BESIFLOXACINActive
Quantity: 6 mg in 1 mL
Code: BFE2NBZ7NX
Classification: ACTIB
MANNITOLInactive
Code: 3OWL53L36A
Classification: IACT
BENZALKONIUM CHLORIDEInactive
Code: F5UM2KM3W7
Classification: IACT
POLYCARBOPHILInactive
Code: W25LM17A4W
Classification: IACT
SODIUM CHLORIDEInactive
Code: 451W47IQ8X
Classification: IACT
SODIUM HYDROXIDEInactive
Code: 55X04QC32I
Classification: IACT
WATERInactive
Code: 059QF0KO0R
Classification: IACT
POLOXAMER 407Inactive
Code: TUF2IVW3M2
Classification: IACT
EDETATE DISODIUMInactive
Code: 7FLD91C86K
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

Besivance - FDA Drug Approval Details